The EPS miss and continued companion animal weakness are the key negatives, partially offset by raised adjusted EPS guidance. Monitor the Q4 earnings call for commentary on companion animal demand trends and the trajectory of the cost restructuring program.
Drugs in focus
ZTS drug pipeline →Alfaxan Multidose 4%
● Neutral Named in this 8-K- Impact
- Phase
- Approved (10 mg/mL); Research/Preclinical (4% formulation)
- Time to market
- The standard 10 mg/mL formulation is already on the market. The 4% concentrated formulation appears to be an experimental/research-stage product with no publicly disclosed regulatory submission or commercialization timeline.
- Next catalyst
- None dated
What to watchAlfaxan Multidose 4% has no scheduled regulatory decision or pivotal readout in the next 12 months. The standard 10 mg/mL formulation is already marketed. Watch for any FDA submission or label expansion for the 4% concentrated formulation, but none is currently visible. Zoetis's stock moves on company-wide earnings and its large dermatology/parasiticide portfolio, not on this single anesthetic product.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $82.11entry
- T+1 · 11d ago −3.30%α −3.61% · $79.40
- T+5 · 5d ago +1.04%α −2.26% · $82.96
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zoetis Q3 2026 revenue of $2.391B was slightly above the $2.30B consensus, but GAAP net income fell 18% YoY to $591M and GAAP diluted EPS of $1.44 missed the $1.51 consensus. The company narrowed its full-year revenue guidance and raised its adjusted EPS guidance, reflecting ongoing pressure in companion animal markets offset by livestock growth.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $2.391B, down 1% YoY reported and organic operational
- GAAP diluted EPS $1.44, down 12% YoY, missing consensus of $1.51
- Adjusted diluted EPS $1.75, up 3% reported and 1% organic operational
- U.S. segment revenue down 6% YoY; International up 4%
- Companion animal revenue declined 5% YoY; Livestock grew 7%
- Full-year 2026 revenue guidance narrowed to $9.220B-$9.320B (organic operational growth -2% to -1%)
- Full-year 2026 adjusted diluted EPS guidance raised to $6.25-$6.35 from $6.15-$6.25
- GAAP net income $591M, down 18% YoY; adjusted net income $720M, down 5%
- Q3 included $129M in purchase accounting, acquisition/divestiture costs and certain significant items
Financial Impact
Revenue $2.391B vs consensus $2.30B; GAAP EPS $1.44 vs consensus $1.51; adjusted EPS $1.75 vs prior year $1.70
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| U.S. | $1.2B | -6.0% |
| International | $1.1B | +4.0% |
Risk Factors
- Persistent macro-driven price sensitivity and competitive pressure in companion animal dermatology and parasiticide markets
- Generic competition impacting key brands (Cerenia, Convenia)
- Restructuring charges and asset impairments totaling $133M in Q3 may signal ongoing operational challenges
- U.S. segment revenue declining 6% YoY with companion animal down 8%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001555280-26-000048 |
| Document: zts-20261105.htm | 0001555280-26-000048 |
| Document: 0001555280-26-000048-index-headers.html | 0001555280-26-000048 |
| Document: 0001555280-26-000048-index.html | 0001555280-26-000048 |
| Document: 0001555280-26-000048.txt | 0001555280-26-000048 |
| 8-K Data (Synthetic) | 0001555280-26-000048 |
Track record
10 reports on ZTS
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +38.10% at T+60 after the Feb 27, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $82.11 to $79.40 Now $84.39 −2.78% ▲ +3.30% +3.61% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $79.52 to $79.96 Now $84.39 +6.13% ▲ +0.55% +0.22% vs SPY
- Oct 13, 20264w ago 8-K Neutral 2/10 Entry $74.30 to $75.29 Now $84.39 +13.58% ▲ +1.33% +2.41% vs SPY
- Oct 8, 20265w ago 8-K Neutral 2/10 Entry $74.81 to $75.65 Now $84.39 +12.81% ▲ +1.12% +1.18% vs SPY
- Aug 6, 202614w ago 8-K Bearish 7/10 Entry $77.05 to $72.36 Now $84.39 −9.53% ▲ +6.09% +6.70% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $79.98 to $81.17 Now $84.39 +5.52% ▲ +1.49% +1.04% vs SPY
- May 13, 202626w ago Insider Cluster Neutral 2/10 Entry $75.24 to $73.62 Now $84.39 +12.16% ▼ −2.15% −0.93% vs SPY
- May 7, 202627w ago 8-K Bearish 7/10 Entry $87.24 to $82.31 Now $84.39 +3.27% ▲ +5.65% +6.48% vs SPY
- Apr 8, 202631w ago DEFA14A Neutral 2/10 Entry $119.65 to $119.47 Now $84.39 −29.47% ▼ −0.15% −0.72% vs SPY
- Feb 27, 202637w ago Court Ruling Bearish 6/10 Entry $127.51 to $124.52 Now $84.39 +33.82% ▲ +2.35% +1.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers